Forum Topic News
  • Conversation: Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

    • August 20, 2018 4:33 PM BST
    • Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

      Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.
      The acquisition gives Novo Nordisk full rights to Ziylo's glucose binding molecule platform to develop glucose responsive insulins. The development of glucose responsive insulins is a key strategic area for Novo Nordisk in its effort to develop this next generation of insulin which would lead to a safer and more effective insulin therapy. A glucose responsive insulin would help eliminate the risk of hypoglycaemia, which is the main risk associated with insulin therapy and one of the main barriers for achieving optimal glucose control. Thus, a glucose responsive insulin could also lead to better metabolic control and thus overall reduce the burden of diabetes for people living with the disease.
      Read more: http://www.worldpharmanews.com/novonordisk/4515-novo-nordisk-acquires-ziylo-ltd-to-accelerate-its-development-of-glucose-responsive-insulins

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč